The quality of life measure is becoming more important in determining the effectiveness of different treatment options and the development of clinical pathways.
Authors look at how frameworks proposed by various organizations are useful for assessing the value of different treatments.
Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer’s Treatments?
Authors take a look at how improved diagnostic testing can lead to better care for patients with Alzheimer's disease.
Authors discuss aspects of medication that can provide different results for patients, such as formulation, route of administration, device, or packaging.
Omitting radiotherapy for women with low-risk luminal A breast cancer would produce significant cost savings without adversely affecting outcomes.
This issue of Journal of Clinical Pathways aims to improve how health-related quality of life should be assessed and its impact on patient outcomes.
Companion Diagnostics and Complementary Diagnostics in Clinical Practice: Better Medicine or Competitive Disadvantage?
Authors weigh the benefits and shortcomings of companion diagnostics.
Richard G Stefanacci and his coauthors describe how clinical pathways can be designed to achieve the Triple Aim of care.
Transparency of the evidence synthesis and clinical pathway development processes will be key to ensuring buy-in among stakeholders.
The authors explore how incorporating the role of patient navigators into AD clinical pathways can result in improved outcomes for patients.